Briefing to Cover U.S. Pharma Supply Chain Onshoring, Trade Policy Shifts
U.S. pharmaceutical and life sciences manufacturers, product developers, and supply chain stakeholders must track emerging onshoring mandates, supply chain disclosure rules, and user fee-linked manufacturing requirements that will reshape domestic production and procurement strategies.
The U.S. administration is advancing multiple overlapping policy initiatives to onshore pharmaceutical supply chains, including Section 232 national security investigations into finished pharmaceuticals and active pharmaceutical ingredients (APIs), updated Trade Agreements Act procurement disclosure requirements that may prioritize U.S.-origin components, and pending reauthorizations of GDUFA IV and PDUFA VIII that could tie user fee structures to manufacturing location. Recent tariff proposals for APIs and patented pharmaceuticals, paired with exemptions for generic drugs, biosimilars, and certain 505(b)(2) products, create a complex, shifting regulatory landscape. In-house counsel for U.S. life sciences manufacturers, product developers, and supply chain stakeholders should monitor these developments, audit supply chain origin compliance, and engage with policy negotiations to align manufacturing and procurement strategies with emerging requirements.